Filing Flows › Companies › Chemours › Timeline
Chemours stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+11.0% to $12.75
Chemours (CC) stock rose 11% over the last 252 sessions, to $12.75. On the way it reported 5 quarters, its insiders filed 7 open-market trades, and the company filed 5 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 2, 2026 | Earnings | Earnings: missed the EPS estimate by -18.5% | −2.8% (−2.3% vs SPY) | −5.9% (−3.2% vs SPY) | — |
| Sep 10, 2026 | 8-K | Material definitive agreement | +0.2% (+0.8% vs SPY) | −4.2% (−3.1% vs SPY) | −8.4% (−10.2% vs SPY) |
| Aug 12, 2026 | Insider buy | Familiar Calderon Gerardo bought $30K | +2.9% (+2.7% vs SPY) | +4.7% (+5.1% vs SPY) | +2.4% (+4.1% vs SPY) |
| Aug 11, 2026 | Insider buy | Dignam Denise bought $51K | +1.4% (+1.8% vs SPY) | +8.0% (+8.1% vs SPY) | +3.6% (+5.0% vs SPY) |
| Aug 7, 2026 | Insider buy | Martinko Joseph T. bought $30K | +4.2% (+3.5% vs SPY) | +1.0% (−0.2% vs SPY) | +1.8% (+1.6% vs SPY) |
| Aug 7, 2026 | Insider buy | Foley Michael Robert bought $30K | +4.2% (+3.5% vs SPY) | +1.0% (−0.2% vs SPY) | +1.8% (+1.6% vs SPY) |
| Aug 7, 2026 | Insider buy | Cowan Alister bought $203K | +4.2% (+3.5% vs SPY) | +1.0% (−0.2% vs SPY) | +1.8% (+1.6% vs SPY) |
| Aug 7, 2026 | Insider buy | Cranston Mary B bought $95K | +4.2% (+3.5% vs SPY) | +1.0% (−0.2% vs SPY) | +1.8% (+1.6% vs SPY) |
| Aug 6, 2026 | Insider buy | Hostetter Shane bought $50K | +3.5% (+3.7% vs SPY) | +4.4% (+4.0% vs SPY) | +6.5% (+6.1% vs SPY) |
| Aug 4, 2026 | Earnings | Earnings: beat the EPS estimate by 0.1% | +4.7% (+2.9% vs SPY) | −15.9% (−17.9% vs SPY) | −11.9% (−12.5% vs SPY) |
| Jun 24, 2026 | 8-K | Material definitive agreement | +5.9% (+5.9% vs SPY) | +2.8% (+1.0% vs SPY) | −13.3% (−13.9% vs SPY) |
| May 5, 2026 | Earnings | Earnings: beat the EPS estimate by 223.8% | +2.6% (+1.8% vs SPY) | −7.5% (−10.4% vs SPY) | −18.2% (−23.1% vs SPY) |
| Apr 30, 2026 | 8-K | Directors and officers: departures, appointments, pay | +2.8% (+2.6% vs SPY) | −18.4% (−20.2% vs SPY) | −18.5% (−23.9% vs SPY) |
| Mar 12, 2026 | 8-K | Material definitive agreement | −0.7% (−0.2% vs SPY) | +6.8% (+7.7% vs SPY) | +26.4% (+23.2% vs SPY) |
| Feb 19, 2026 | Earnings | Earnings: beat the EPS estimate by 192.1% | −3.6% (−3.3% vs SPY) | −16.0% (−17.0% vs SPY) | −10.5% (−6.6% vs SPY) |
| Jan 16, 2026 | 8-K | Material definitive agreement | +0.3% (+0.4% vs SPY) | +1.2% (+1.7% vs SPY) | +28.5% (+29.9% vs SPY) |
| Nov 6, 2025 | Earnings | Earnings: missed the EPS estimate by -17.2% | −2.6% (−1.5% vs SPY) | +4.5% (+3.7% vs SPY) | +6.0% (+4.8% vs SPY) |
Insiders’ record here
In the year on the chart, Chemours' insiders reported 7 open-market buys ($489K) and 0 sales ($0).
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Chemours: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.